{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:59:20Z","timestamp":1777658360437,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Municipal Health Commission Health Industry Clinical Research Special Project","award":["20254Y0060"],"award-info":[{"award-number":["20254Y0060"]}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["25ZR1402080"],"award-info":[{"award-number":["25ZR1402080"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004750","name":"Aeronautical Science Foundation of China","doi-asserted-by":"publisher","award":["82272035"],"award-info":[{"award-number":["82272035"]}],"id":[{"id":"10.13039\/501100004750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00259-025-07734-w","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:05:31Z","timestamp":1768525531000},"page":"3817-3826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Granzyme B PET\/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers"],"prefix":"10.1007","volume":"53","author":[{"given":"Qiufang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jindian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2544-7522","authenticated-orcid":false,"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"7734_CR1","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/S0140-6736(25)00052-2","volume":"405","author":"R Sundar","year":"2025","unstructured":"Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet. 2025;405:2087\u2013102.","journal-title":"Lancet"},{"key":"7734_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"7734_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57.","journal-title":"J Hematol Oncol"},{"key":"7734_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, Osumi H, Yoshino K, Yamaguchi K. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27:907\u201331.","journal-title":"Gastric Cancer"},{"key":"7734_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andre","year":"2023","unstructured":"Andre T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch Repair\/Microsatellite Instability-High gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41:255\u201365.","journal-title":"J Clin Oncol"},{"key":"7734_CR6","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330:2064\u201374.","journal-title":"JAMA"},{"key":"7734_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"7734_CR8","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.","journal-title":"JAMA Oncol"},{"key":"7734_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus Paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333.","journal-title":"Lancet"},{"key":"7734_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","volume":"29","author":"YJ Bang","year":"2018","unstructured":"Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300. Ann Oncol. 2018;29:2052\u201360.","journal-title":"Ann Oncol"},{"key":"7734_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10120-021-01227-z","volume":"25","author":"CS Fuchs","year":"2022","unstructured":"Fuchs CS, Ozguroglu M, Bang YJ, et al. Pembrolizumab versus Paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022;25:197\u2013206.","journal-title":"Gastric Cancer"},{"key":"7734_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/1078-0432.CCR-20-3243","volume":"27","author":"VL Nagle","year":"2021","unstructured":"Nagle VL, Henry KE, Hertz CAJ, et al. Imaging Tumor-Infiltrating lymphocytes in brain tumors with [(64)Cu]Cu-NOTA-anti-CD8 PET. Clin Cancer Res. 2021;27:1958\u201366.","journal-title":"Clin Cancer Res"},{"key":"7734_CR13","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1158\/0008-5472.CAN-19-3265","volume":"80","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Mayer AT, Nobashi TW, Gambhir SS. ICOS is an indicator of T-cell-Mediated response to cancer immunotherapy. Cancer Res. 2020;80:3023\u201332.","journal-title":"Cancer Res"},{"key":"7734_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0014-2964(79)90225-1","volume":"15","author":"HJ Saxholm","year":"1979","unstructured":"Saxholm HJ, Reith A. The surface structure of 7,12-dimethylbenz(a)anthracene transformed C3H\/10T 1\/2 cells. A quantitative scanning electron microscopical study. Eur J Cancer (1965). 1979;15:843\u201355.","journal-title":"Eur J Cancer (1965)"},{"key":"7734_CR15","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77:2318\u201327.","journal-title":"Cancer Res"},{"key":"7734_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12951-021-00785-9","volume":"19","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wang C, Yang Y, et al. ImmunoPET imaging of human CD8(+) T cells with novel (68)Ga-labeled nanobody companion diagnostic agents. J Nanobiotechnol. 2021;19:42.","journal-title":"J Nanobiotechnol"},{"key":"7734_CR17","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41592-020-0934-5","volume":"17","author":"AW Woodham","year":"2020","unstructured":"Woodham AW, Zeigler SH, Zeyang EL, et al. In vivo detection of antigen-specific CD8(+) T cells by immuno-positron emission tomography. Nat Methods. 2020;17:1025\u201332.","journal-title":"Nat Methods"},{"key":"7734_CR18","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, et al. CD8-Targeted PET imaging of Tumor-Infiltrating T cells in patients with cancer: A phase I First-in-Humans study of (89)Zr-Df-IAB22M2C, a radiolabeled Anti-CD8 minibody. J Nucl Med. 2022;63:720\u20136.","journal-title":"J Nucl Med"},{"key":"7734_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.121.261976","volume":"63","author":"C Li","year":"2022","unstructured":"Li C, Han C, Duan S, Li P, Alam IS, Xiao Z. Visualizing T-Cell responses: the T-Cell PET imaging toolbox. J Nucl Med. 2022;63:183\u20138.","journal-title":"J Nucl Med"},{"key":"7734_CR20","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1172\/JCI98509","volume":"128","author":"IS Alam","year":"2018","unstructured":"Alam IS, Mayer AT, Sagiv-Barfi I, et al. Imaging activated T cells predicts response to cancer vaccines. J Clin Invest. 2018;128:2569\u201380.","journal-title":"J Clin Invest"},{"key":"7734_CR21","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-18-0253","volume":"78","author":"HM Gibson","year":"2018","unstructured":"Gibson HM, McKnight BN, Malysa A, et al. IFNgamma PET imaging as a predictive tool for monitoring response to tumor immunotherapy. Cancer Res. 2018;78:5706\u201317.","journal-title":"Cancer Res"},{"key":"7734_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM, Bloch E, Nesti S, et al. The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging. Clin Cancer Res. 2019;25:1196\u2013205.","journal-title":"Clin Cancer Res"},{"key":"7734_CR23","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, et al. (68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15:8791.","journal-title":"Nat Commun"},{"key":"7734_CR24","doi-asserted-by":"crossref","unstructured":"Zhou H, Wang Y, Xu H et al. Noninvasive interrogation of CD8\u2009+\u2009T cell effector function for monitoring early tumor responses to immunotherapy. J Clin Invest 2022;132:e161065.","DOI":"10.1172\/JCI161065"},{"key":"7734_CR25","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2967\/jnumed.124.267529","volume":"65","author":"Q Liu","year":"2024","unstructured":"Liu Q, Xu X, Yang Z, et al. Granzyme B PET\/CT imaging evaluates early response to immunotherapy in gastric cancer. J Nucl Med. 2024;65:1695\u2013701.","journal-title":"J Nucl Med"},{"key":"7734_CR26","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20139.","journal-title":"Clin Cancer Res"},{"key":"7734_CR27","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/RLU.0000000000005515","volume":"49","author":"Y Lee","year":"2024","unstructured":"Lee Y, Won HS, Seo KJ, Na SJ. FDG PET images of pseudoprogression after Nivolumab-FOLFOX chemotherapy in a gastric cancer patient. Clin Nucl Med. 2024;49:1139\u201341.","journal-title":"Clin Nucl Med"},{"key":"7734_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Schoder H, et al. (18)F-FDG PET\/CT for monitoring of ipilimumab therapy in patients with metastatic melanoma. J Nucl Med. 2019;60:335\u201341.","journal-title":"J Nucl Med"},{"key":"7734_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CJI.0000000000000458","volume":"46","author":"TH Chen","year":"2023","unstructured":"Chen TH, Chen MH, Hung YP, et al. Elevated PD-L1 expression and microsatellite instability in elderly patients with gastric cancer. J Immunother. 2023;46:111\u20139.","journal-title":"J Immunother"},{"key":"7734_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5230\/jgc.2025.25.e4","volume":"25","author":"Y Cho","year":"2025","unstructured":"Cho Y, Ahn S, Kim KM. PD-L1 as a biomarker in gastric cancer immunotherapy. J Gastric Cancer. 2025;25:177\u201391.","journal-title":"J Gastric Cancer"},{"key":"7734_CR31","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","volume":"27","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Fuchs CS, Tabernero J, et al. Efficacy of pembrolizumab monotherapy for advanced Gastric\/Gastroesophageal junction cancer with programmed death ligand 1 combined positive score >\/=10. Clin Cancer Res. 2021;27:1923\u201331.","journal-title":"Clin Cancer Res"},{"key":"7734_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00259-023-06527-3","volume":"51","author":"DJ Donnelly","year":"2024","unstructured":"Donnelly DJ, Kim J, Tran T, et al. The discovery and evaluation of [(18)F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. Eur J Nucl Med Mol Imaging. 2024;51:978\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7734_CR33","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1007\/s00259-024-06663-4","volume":"51","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Hsu JC, Hu S, Cai W. PET imaging of PD-L1 with a small molecule Radiotracer. Eur J Nucl Med Mol Imaging. 2024;51:1578\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7734_CR34","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 Blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"key":"7734_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955.","journal-title":"Cell Death Dis"},{"key":"7734_CR36","doi-asserted-by":"publisher","first-page":"e1928","DOI":"10.1002\/wnan.1928","volume":"16","author":"X Li","year":"2024","unstructured":"Li X, Chen G, Wu K, et al. Imaging and monitoring of granzyme B in the immune response. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024;16:e1928.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"7734_CR37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41:1470\u201391.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07734-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07734-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:25:58Z","timestamp":1777274758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07734-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["7734"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07734-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Fudan University Shanghai Cancer Cetner (approval No. 2201249-28) and conducted in accordance with the Declaration of Helsinki. This study was retrospective and the requirement for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors of the manuscript meet the specified criteria for authorship and agreed to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}